Arrowhead Pharmaceuticals, Inc. $ARWR Stock Holdings Lessened by California State Teachers Retirement System

California State Teachers Retirement System decreased its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 3.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 139,826 shares of the biotechnology company's stock after selling 4,487 shares during the quarter. California State Teachers Retirement System owned approximately 0.10% of Arrowhead Pharmaceuticals worth $11,397,217 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its stake in shares of Arrowhead Pharmaceuticals by 285.1% during the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC lifted its position in Arrowhead Pharmaceuticals by 80.6% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 154 shares during the period. Optiver Holding B.V. increased its position in Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company's stock valued at $26,000 after acquiring an additional 186 shares during the last quarter. Persistent Asset Partners Ltd bought a new position in shares of Arrowhead Pharmaceuticals during the second quarter worth $39,000. Finally, Allied Private Wealth LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth approximately $43,000. 62.61% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Citigroup began coverage on Arrowhead Pharmaceuticals in a report on Tuesday, September 8th. They issued a "buy" rating and a $108.00 price objective on the stock. Chardan Capital reaffirmed a "buy" rating and issued a $115.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, August 31st. Wall Street Zen upgraded Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, June 27th. Morgan Stanley increased their target price on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an "overweight" rating in a research report on Thursday, July 23rd. Finally, B. Riley Financial boosted their target price on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. Ten analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $99.15.

Arrowhead Pharmaceuticals Price Performance

ARWR stock traded down $7.89 during trading on Tuesday, reaching $72.78. The company's stock had a trading volume of 2,374,787 shares, compared to its average volume of 2,267,255. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $28.48 and a 1 year high of $95.49. The company has a market capitalization of $10.25 billion, a P/E ratio of -32.32 and a beta of 1.28. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The company's fifty day moving average is $84.18 and its 200-day moving average is $75.22.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The business had revenue of $75.25 million for the quarter, compared to analyst estimates of $44.17 million. During the same quarter in the prior year, the firm earned ($1.26) earnings per share. The company's revenue for the quarter was up 171.0% on a year-over-year basis. On average, research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Adeoye Y. Olukotun sold 2,000 shares of the firm's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the transaction, the director owned 31,600 shares in the company, valued at $2,747,936. This trade represents a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael S. Perry sold 11,600 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the sale, the director owned 111,459 shares in the company, valued at approximately $9,730,370.70. This trade represents a 9.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.60% of the stock is currently owned by insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc NASDAQ: ARWR is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. The company uses RNA interference (RNAi), a biological process that reduces the production of specific proteins, to target conditions that may be difficult to treat with conventional drugs.

Arrowhead's proprietary TRiM platform is designed to deliver RNAi-based therapies to different tissues, including the liver, lungs and other organs. Its investigational pipeline has included candidates for cardiovascular and metabolic diseases, liver disorders, pulmonary conditions and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.